Quantcast
Home > Quotes > IMDZ

Immune Design Corp. Common Stock (IMDZ) Quote & Summary Data

IMDZ 
$1.42
*  
0.01
0.71%
Get IMDZ Alerts
*Delayed - data as of Nov. 15, 2018  -  Find a broker to begin trading IMDZ now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    IMDZ After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.30 / $ 1.45
Today's High / Low
$ 1.45 / $ 1.36
Share Volume
268,436
50 Day Avg. Daily Volume
530,678
Previous Close
$ 1.41
52 Week High / Low
$ 5.05 / $ 1.29
Market Cap
68,394,056
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
268,436
50 Day Avg. Daily Volume:
530,678

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.15

Trading Range

The current last sale of $1.42 is 10.08% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.45 $ 5.05
 Low: $ 1.36 $ 1.29

Company Description (as filed with the SEC)

We are a late-stage immunotherapy company employing next-generation, diversified in vivo approaches designed to enable the body's immune system to fight disease. Although we believe our approaches have broad potential across multiple therapeutic areas, we are focused in oncology and have designed our technologies to activate the immune system's natural ability to generate and/or expand tumor-specific cytotoxic T cells, or CTLs, while also enhancing other immune effectors, to fight cancer via distinct mechanisms. CMB305 and G100, our lead product candidates, use the body's immune system in different ways that, we believe, address the shortcomings of other therapies and have the potential to treat a broad patient population either as monotherapies or in combination with other mechanisms of action. In 2017, we presented positive single-arm and randomized data for CMB305 and G100 in soft tissue sarcoma and follicular NHL patients, respectively, and after meeting with the U.S.  ... More ...  


Risk Grade

Where does IMDZ fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.38
Open Date:
Nov. 15, 2018
Close Price:
$ 1.42
Close Date:
Nov. 15, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x